“…Meta-analyses of other treatments, such as like glucagon-like peptide-1 receptor agonists and negative allosteric modulators of 5-hydroxytryptamine 2A receptors, were also conducted by the researchers across the globe. 75,76 Our meta-analysis showed that all 3 acetylcholinesterase inhibitors now in use, i.e., donepezil, galantamine and galantamine, significantly enhance patients' cognitive abilities. However, given to the substantial heterogeneity among the included trials, caution should be exercised in interpreting the results of galantamine and rivastigmine.…”